Antimicrobial-resistant Shigella infections from Iran : an overlooked problem?

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Standard

Antimicrobial-resistant Shigella infections from Iran : an overlooked problem?. / Tajbakhsh, Mercedeh; García Migura, Lourdes; Rahbar, Mohammad; Svendsen, Christina Aaby; Mohammadzadeh, Mona; Zali, Mohammad Reza; Aarestrup, Frank M.; Hendriksen, Rene S.

In: Journal of Antimicrobial Chemotherapy, Vol. 67, No. 5, 2012, p. 1128-1133.

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Harvard

APA

CBE

MLA

Vancouver

Tajbakhsh M, García Migura L, Rahbar M, Svendsen CA, Mohammadzadeh M, Zali MR et al. Antimicrobial-resistant Shigella infections from Iran: an overlooked problem?. Journal of Antimicrobial Chemotherapy. 2012;67(5):1128-1133. Available from: 10.1093/jac/dks023

Author

Tajbakhsh, Mercedeh; García Migura, Lourdes; Rahbar, Mohammad; Svendsen, Christina Aaby; Mohammadzadeh, Mona; Zali, Mohammad Reza; Aarestrup, Frank M.; Hendriksen, Rene S. / Antimicrobial-resistant Shigella infections from Iran : an overlooked problem?.

In: Journal of Antimicrobial Chemotherapy, Vol. 67, No. 5, 2012, p. 1128-1133.

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Bibtex

@article{f784635d0ca34158a045612b1267b833,
title = "Antimicrobial-resistant Shigella infections from Iran",
publisher = "Oxford University Press",
author = "Mercedeh Tajbakhsh and {García Migura}, Lourdes and Mohammad Rahbar and Svendsen, {Christina Aaby} and Mona Mohammadzadeh and Zali, {Mohammad Reza} and Aarestrup, {Frank M.} and Hendriksen, {Rene S.}",
year = "2012",
doi = "10.1093/jac/dks023",
volume = "67",
number = "5",
pages = "1128--1133",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",

}

RIS

TY - JOUR

T1 - Antimicrobial-resistant Shigella infections from Iran

T2 - an overlooked problem?

A1 - Tajbakhsh,Mercedeh

A1 - García Migura,Lourdes

A1 - Rahbar,Mohammad

A1 - Svendsen,Christina Aaby

A1 - Mohammadzadeh,Mona

A1 - Zali,Mohammad Reza

A1 - Aarestrup,Frank M.

A1 - Hendriksen,Rene S.

AU - Tajbakhsh,Mercedeh

AU - García Migura,Lourdes

AU - Rahbar,Mohammad

AU - Svendsen,Christina Aaby

AU - Mohammadzadeh,Mona

AU - Zali,Mohammad Reza

AU - Aarestrup,Frank M.

AU - Hendriksen,Rene S.

PB - Oxford University Press

PY - 2012

Y1 - 2012

N2 - Objectives: In this study, we wanted to assess the level of antimicrobial resistance, the presence of genes encoding resistance to cephalosporins and plasmid-mediated quinolone resistance (PMQR), and genetic relatedness among Shigella isolates obtained from Iranian patients. ; Methods: A total of 44 Shigella isolates were collected from Iranian patients admitted to Milad Hospital, Tehran, Iran, during 2008–10. Of these, 37 were serotyped and characterized by MIC determination. A subset of eight suspected extended-spectrum β-lactamase (ESBL) producers (six Shigella sonnei phase II and two Shigella flexneri type 1b) were examined for the presence of genes encoding cephalosporin resistance. The presence of PMQR was assessed in one S. flexneri isolate exhibiting low-level resistance to ciprofloxacin and susceptibility to nalidixic acid. PFGE was performed on 25 S. sonnei phase II isolates. ; Results: Of the isolates, 25 (68%) were S. sonnei phase II, with 5 (14%) S. flexneri, 5 (14%) Shigella dysenteriae type 2, and 2 (5%) Shigella boydii type 2. Resistance to at least threeclasses of antimicrobials was detected in all species. The presence of blaCTX-M-15 and the AmpC β-lactamase producer blaCMY-2 was confirmed in five and one S. sonnei phase II isolates, respectively. One of the two S. flexneri type 1b that contained blaCTX-M-15 also harboured a qnrS1 gene. PFGE identified sevenPFGE profiles; the main cluster included 15 of the strains, suggesting low genetic diversity between isolates or the presence of an endemic clone in Iran. ; Conclusions: This is the first known description of ESBL-producing and AmpC β-lactamase-producing Shigella and of PMQR Shigella in Iran. The emergence of CTX-15, CMY-2 and qnrS1 genes may compromise the treatment of shigellosis. Strategies to minimize the spread of ESBL-producing and AmpC-β-lactamase-producing Shigella should be implemented.

AB - Objectives: In this study, we wanted to assess the level of antimicrobial resistance, the presence of genes encoding resistance to cephalosporins and plasmid-mediated quinolone resistance (PMQR), and genetic relatedness among Shigella isolates obtained from Iranian patients. ; Methods: A total of 44 Shigella isolates were collected from Iranian patients admitted to Milad Hospital, Tehran, Iran, during 2008–10. Of these, 37 were serotyped and characterized by MIC determination. A subset of eight suspected extended-spectrum β-lactamase (ESBL) producers (six Shigella sonnei phase II and two Shigella flexneri type 1b) were examined for the presence of genes encoding cephalosporin resistance. The presence of PMQR was assessed in one S. flexneri isolate exhibiting low-level resistance to ciprofloxacin and susceptibility to nalidixic acid. PFGE was performed on 25 S. sonnei phase II isolates. ; Results: Of the isolates, 25 (68%) were S. sonnei phase II, with 5 (14%) S. flexneri, 5 (14%) Shigella dysenteriae type 2, and 2 (5%) Shigella boydii type 2. Resistance to at least threeclasses of antimicrobials was detected in all species. The presence of blaCTX-M-15 and the AmpC β-lactamase producer blaCMY-2 was confirmed in five and one S. sonnei phase II isolates, respectively. One of the two S. flexneri type 1b that contained blaCTX-M-15 also harboured a qnrS1 gene. PFGE identified sevenPFGE profiles; the main cluster included 15 of the strains, suggesting low genetic diversity between isolates or the presence of an endemic clone in Iran. ; Conclusions: This is the first known description of ESBL-producing and AmpC β-lactamase-producing Shigella and of PMQR Shigella in Iran. The emergence of CTX-15, CMY-2 and qnrS1 genes may compromise the treatment of shigellosis. Strategies to minimize the spread of ESBL-producing and AmpC-β-lactamase-producing Shigella should be implemented.

U2 - 10.1093/jac/dks023

DO - 10.1093/jac/dks023

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 5

VL - 67

SP - 1128

EP - 1133

ER -